The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Fatty Acid-Binding Protein 1 as a Potential New Serological Marker of Liver Status in Children with Wilson Disease
J Pediatr Gastroenterol Nutr. 2021 Mar 17. doi: 10.1097/MPG.0000000000003128.Online ahead of print.
Joanna Beata Bierla1, Wojciech Janczyk, Ewa Konopka, Aldona Wierzbicka-Rucinska, Sebastian Wieckowski, Lukasz Obrycki, Jedrzej Sarnecki, Ewelina Kanarek, Bozena Cukrowska, Piotr Socha
1*Department of Pathomorphology, IPCZD, Warsaw, Poland †Department of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, IPCZD, Warsaw, Poland ‡Department of Biochemistry, Radioimmunology and Experimental Medicine, IPCZD, Warsaw, Poland §Department of Nephrology and Arterial Hypertension, IPCZD, Warsaw, Poland ||Department of Radiology, IPCZD, Warsaw, Poland.
Objectives: Wilson's disease (WD) is a copper metabolism disorder with toxic copper accumulation in the liver leading to liver steatosis or fibrosis. In vitro studies suggest that fatty acid-binding protein 1 (L-FABP) and lipid droplet-associated protein 5 (PLIN5) may have an impact on both processes, but knowledge about these potential biomarkers is insufficient in the case of WD. Thus, the aim of this study was to determine L-FABP and PLIN5 levels in sera of WD patients in relation to liver steatosis/fibrosis.
Methods: The final study involved 74 WD children in whom liver steatosis (WD1 subgroup, n = 28) and fibrosis (WD2 subgroup, n = 13) were assessed with the use of transient elastography. Control groups included WD children without steatosis and fibrosis (WD0 subgroup, n = 33) and healthy children (n = 75). L-FABP and PLIN5 measurements were performed in sera with the use of the immunoenzymatic method.
Results: L-FABP was significantly higher in the WD2 subgroup, and the correlation between L-FABP concentration and liver fibrosis was confirmed statistically by regression analysis (p = 0.04) with Pearson's coefficient r = 0.24. L-FABP was significantly correlated with aminotransferase ALT (r = 0.42) and AST (r = 0.37) activity. PLIN5 concentration was similar in all groups and was not related to steatosis and fibrosis.
Conclusions: Our results suggest that serum L-FABP could be a novel biomarker of liver fibrosis in WD children.